ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in several solid tumors including brain metastases, but single agent ICIs have failed to improve outcome in recurrent (GBM). This study evaluated the safety of anti-CTLA-4 (IPI) and anti-PD-1 (NIVO) ICIs alone or in combina...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Gilbert, Mark, Zhang, Peixin, Sloan, Andrew, Aldape, Kenneth, Wu, Jing, Rogers, Lisa, Wen, Patrick, Barani, Igor, Iwamoto, Fabio, Raval, Raju, Voloshin, Alfredo, de Groot, John, Won, Minhee, Mehta, Minesh P
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216145/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.024
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia